Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

JPMorgan analyst Jessica Fye lowered the firm’s price target on Moderna (MRNA) to $59 from $70 and keeps an Underweight rating on the shares. The firm updated estimates following Pfizer’s Comirnaty ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other most promising gene ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The United Nations Convention on Biological Diversity, or COP16, ended on Nov. 2. Several days before delegations from 177 ...

Current Moderna shareholders who have held Moderna shares since on or before January 18, 2023, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a ...

Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: ...

We recently published a list of the 10 Worst Performing Stocks in S&P 500 in 2024. In this article, we are going to take a ...

Shares of Moderna Inc. MRNA shed 0.91% to $54.72 Wednesday, on what proved to be an all-around poor trading session for the ...